tbuckley/cabot-search huggingface dataset:
Migraines—The Parable of the People Who Were Blind and the Elephant
Authors: Bruce M. Rothschild
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Les cas de Neisseria meningitidis en Grèce
Authors: J Kremastinou, G Tzanakaki, N Vakalis, A Velonaki
Journal: Eurosurveillance (1997)

En Grece, les cas d'infection a Neisseria meningitidis sont sporadiques, avec quelques epidemies locales saisonnieres. La declaration des infections a meningocoque aux autorites sanitaires locales et au ministere de la sante est obligatoire. En 1994, le Centre National de Reference des Meningocoques (CNM) a ete reactive pour developper un reseau entre les hopitaux et les autorites sanitaires locales afin d'ameliorer le systeme de declaration.
MP0250 – a dual inhibitor of VEGF and HGF - plus bortezomib + dexamethasone in a phase 2 open-label, single-arm, multicenter trial in patients with refractory and relapsed multiple myeloma (RRMM)
Authors: M.S. Raab, R. Ria, J. Schlenzka, T. Krahnke, J. Haunschild, F. Herrmann, U. Fiedler, K. Dawson, M.T. Stumpp, K. Tadjalli Mehr, A. Harstrick, A. Vacca, H. Goldschmidt
Journal: Annals of Oncology (2017)
KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
Authors: R.S. Finn, S.L. Chan, A.X. Zhu, J. Knox, A-L. Cheng, A.B. Siegel, O. Bautista, M. Kudo
Journal: Annals of Oncology (2017)
Modified ketogenic diet in advanced malignancies - final results of a safety and feasibility trial within the Veterans Affairs Healthcare System.
Authors: Jocelyn Tan-Shalaby, Jennifer Carrick, Krystal Edinger, Dana Genovese, Andrew D. Liman, Vida Almario Passero, Rashmikant Shah
Journal: Journal of Clinical Oncology (2016)

e23173 Final report of a safety and feasibility trial within the Pittsburgh Veteran Affairs HealthCare System- Modified Ketogenic Diet in Advanced Cancer Background: ,Malignant cells have dysfunctional mitochondria which limit their ability to use energy from fatty acids and ketones. Pre-clinical animal studies using a ketogenic diet in cancer show encouraging results. We tested safety and feasibility of the modified ketogenic diet in a veteran population of advanced cancer patients across a variety of solid tumors. Methods: , We recruited 17 otherwise healthy patients, not on chemotherapy, with advanced or metastatic solid tumors. Dietary instruction on the modified ketogenic diet allowed 20 to 40 grams of carbohydrates daily. Weekly clinical and laboratory assessments were performed until week 4, then every 4 weeks until 16 weeks. Patients answered quality of life questionnaires (EORTC QLQ-c30 version 3) and we monitored side effects, diet tolerability and compliance. Patients underwent PET /CT imaging at baseline, 4,8 and 16 weeks. The primary study endpoint was safety and feasibility. Results: , Seventeen patients enrolled and eleven patients were evaluable. Mean age was 65± 11.7 years, weight 203 ± 4.98 lbs. Mean previous treatment failures was 1.7, ± 0.97. All lost significant body weight and body mass index BMI. Hematologic, biochemical and lipid tests remained stable. Quality of life scores slightly improved but did not significantly change. Six patients (54.5%), five (45.4%) and four (36%) patients had stable or improved disease at 4, 8 and 16 weeks respectively. We saw no correlations between glucose and ketone or lipid parameters. Responders (SD or PR) lost statistically more weight than non-responders. After completing 16 weeks, 3 patients continued on with the diet. Two patients lived for 80 and 116 weeks while the third survived after residual tumor resection with no evidence of disease at 111 weeks. There were no serious side effects. Conclusions: , A modified ketogenic diet is safe and feasible in advanced cancer patients. Quality of life was preserved. Clinical benefit was seen in patients who lost at least 10% of their body weight. Future study is merited. Clinical trial information: NCT01716468.
A MaxDiff survey of chemotherapy patient satisfaction: Identifying key strengths and enhancement opportunities to drive process and quality improvement.
Authors: David Michael Waterhouse, Karyn M. Dyehouse, Patrick J. Ward, Robert Miller, Richard Schiano
Journal: Journal of Clinical Oncology (2014)

e20565 Background: Patient satisfaction surveys using Likert-style rating scales are subject to response, level, and dispersion bias. “MaxDiff” or “worst-best” scaling allows opportunity to determine and quantify the relative importance of satisfaction drivers. The focus of this conjoint survey was to assess satisfaction with factors related to the chemotherapy experience, while simultaneously defining the relative importance of the satisfaction drivers. Methods: Sequential chemotherapy pts at four independent office sites were offered an “in chair” electronic tablet survey. The 38 question survey instrument was adapted from the Community Oncology Alliance Oncology Medical Home (COA OMH) patient satisfaction survey. Sample size was calculated to allow maximum sensitivity for analysis of questions/attributes at a 90% confidence level. MaxDiff scaling (Sawtooth Software) was analyzed using hierarchal Bayes estimation. Comparisons were made between male/female pts, age, length of time as OHC pt, and office site; statistical significance was determined by the Mann-Whiney test. Results: In total, 297 pts of 320 pts (92.8%) responded; mean patient age was 61.7 yrs, 197 female/100 male. MD and staff wait times, professional skills, concern and communication abilities weighed heavily in driving high satisfaction; whereas availability of clinical trials, scheduling, facilities, account, and pharmacy services had low influence. Wait times (higher importance/lower satisfaction) offered the highest enhancement opportunity for process improvement. Both genders had similar priorities for factors driving satisfaction. Wait time, staff and facility satisfaction differed slightly by office. No significant time as OHC pt or age differences were identified. Conclusions: The addition of MaxDiff scaling to conventional patient satisfaction surveys is novel, feasible and acceptable in the community oncology office setting, and can yield relevant, interpretable data. Results of this survey are currently being used to inform ongoing process improvement.
Vigilancia de las resistencias bacterianas a los agentes antimicrobianos en Dinamarca
Authors: D. L. Monnet, H. D. Hemborg, S. R Andersen, C Schöller, T. L. Sørensen, F Bager
Journal: Eurosurveillance (2000)

Los ultimos datos del Programa Integral Danes para la Monitorizacion e Investigacion de Resistencias a los agentes antimicrobianos (Danish Integrated Antimicrobial Resistance Monitoring and Research Programme; DANMAP) muestran que, en Dinamarca, los niveles de resistencia de la Salmonella enterica son bajos y que las resistencias de las cepas de Escherichia coli patogenas en animales deben considerarse como reservorios de resistencias y no como una amenaza para la salud publica. Asimismo, las tendencias de las resistencias de las cepas clinicas de E. coli son coherentes con los patrones de utilizacion de antibioticos en el pais. La resistencia de Staphylococcus aureus y Streptococcus pneumoniae sigue siendo poco frecuente. Sin embargo, la reciente aparicion de resistencias a la penicilina y la eritromicina en S. pneumoniae es preocupante. Por ultimo, la vigilancia de resistencias en bacterias comensales de animales destinados al consumo humano y de los propios alimentos muestra el impacto positivo que, sobre las resistencias, han tenido algunas medidas adoptadas, tales como la prohibicion de la utilizacion de antibioticos como promotores de crecimiento en los animales de granjas.
Sorveglianza delle infezioni sessualmente trasmesse in Inghilterra e Galles
Authors: G Hughes, T Paine, D Thomas
Journal: Eurosurveillance (2001)

La sorveglianza delle infezioni sessualmente trasmesse (IST) in Inghilterra e Galles si e basata nel passato principalmente su dati statistici aggregati forniti da reparti di medicina genito-urinaria al Communicable Disease Surveillance Centre, con il supporto di vari sistemi di notifica di laboratorio. Nonostante questi sistemi forniscano dati di sorveglianza comparativamente robusti, non danno sufficienti informazioni sui fattori di rischio, utili per mirare appropriatamente i programmi di controllo e prevenzione delle IST. Negli ultimi anni, la considerevole crescita delle IST, l'emergenza di numerose epidemie di IST e i cambiamenti nei pattern di resistenza gonococcica hanno richiesto l'introduzione di meccanismi di sorveglianza piu sofisticati. Questo articolo descrive i sistemi correnti di sorveglianza delle IST in Inghilterra e Galles, compresi nuovi sistemi recentemente introdotti o in via di sviluppo, al fine di rispondere alla necessita di ottenere dati di sorveglianza piu dettagliati.
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial
Authors: Linda-Gail Bekker, Surita Roux, Elaine Sebastien, Ntando Yola, K Rivet Amico, James P Hughes, Mark A Marzinke, Craig W Hendrix, Peter L Anderson, Vanessa Elharrar, Michael Stirratt, James F Rooney, Estelle Piwowar-Manning, Susan H Eshleman, Laura McKinstry, Maoji Li, Bonnie J Dye, Robert M Grant
Journal: The Lancet HIV (2017)
5-ALA administration for photodynamic diagnosis of peritoneal metastases due to advanced gastric cancer: A randomised, double-blind, multicentre phase I/II study
Authors: T. Takahashi, K. Fujitani, T. Omori, K. Nishikawa, T. Hayashi, T. Namikawa, E. Otsuji, S. Takiguchi, Y. Doki
Journal: Annals of Oncology (2017)
Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
Authors: Steven Francis Powell, Mark Mutuota Gitau, Christopher Joseph Sumey, John T. Reynolds, Michele Lohr, Steven McGraw, Ryan Kenneth Nowak, Andrew M Terrell, Ashley Wayne Jensen, Miran Joel Blanchard, Christie Ellison, Lora Jane Black, Paul A. Thompson, Kathryn A. Gold, Ezra E.W. Cohen, John H. Lee, William Charles Spanos
Journal: Journal of Clinical Oncology (2017)

6011 Background: Pembrolizumab (pembro) is a humanized monoclonal antibody that blocks the programmed death receptor-1 (PD-1) interaction with its ligands (PD-L1, PD-L2). While pembro is approved for platinum-refractory, recurrent/metastatic SCCHN, its role in definitive therapy for LA-SCCHN is not yet defined. Here we present the safety results of pembro with cisplatin-based CRT for patients (pts) with LA-SCCHN (NCT02586207). Methods: 27 pts with oropharyngeal (OP), hypopharyngeal (HP), and laryngeal (L) stage III-IVB SCCHN (any HPV status) eligible for cisplatin-based, definitive CRT were enrolled from November 2015 to August 2016 as part of a safety cohort. Pembro was given at a fixed dose of 200 mg IV 4-7 days prior to initiation of CRT and then every 3 weeks during CRT (2 concomitant doses) and then following CRT for 5 additional doses. CRT consisted of weekly cisplatin 40 mg/m2 IV x 6 doses (240 mg/m2 maximum) given concurrently with radiation at a dose of 2 Gy once daily for 35 fractions (total 70 Gy). Safety was determined by the occurrence of CRT or pembro dose-limiting adverse events (AEs) and immune-related AEs (irAEs). Efficacy was defined as complete response (CR) rate on imaging or with salvage surgery at 100 days post-CRT completion. Results: 20 (74%) pts with OP HPV+ and 7 (26%) pts with HPV- (4 L, 2 OP, 1 HP) tumors were enrolled. 21 (78%) completed all planned doses of pembro. 3 discontinued due to irAEs (G2 peripheral motor neuropathy, G3 AST elevation, G1 Lhermitte-like syndrome). 3 discontinued due to protocol reasons (early neck dissection -2 pts, prolonged hospitalization-1 pt). All pts completed the full radiation dose (70 Gy) without significant delay (defined as &gt; 5 days). 23 (85%) received the goal target dose of cisplatin (≥200 mg/m2). There was one pt death due to concurrent illness, unrelated to treatment. The study has been reopened with expansion cohorts of 34 HPV+ pts and 23 HPV- pts to evaluate efficacy. Conclusions: Pembro in combination with weekly cisplatin-based CRT is safe and does not significantly impair radiation or chemotherapy dosing. Efficacy of this combination is being explored further in this study and through larger phase III clinical trials. Clinical trial information: NCT02586207.
Preparation of Chitin-PLA laminated composite for implantable application
Authors: Romana Nasrin, Shanta Biswas, Taslim Ur Rashid, Sanjida Afrin, Rumana Akhter Jahan, Papia Haque, Mohammed Mizanur Rahman
Journal: Bioactive Materials (2017)

The present study explores the possibilities of using locally available inexpensive waste prawn shell derived chitin reinforced and bioabsorbable polylactic acid (PLA) laminated composites to develop new materials with excellent mechanical and thermal properties for implantable application such as in bone or dental implant. Chitin at different concentration (1-20% of PLA) reinforced PLA films (CTP) were fabricated by solvent casting process and laminated chitin-PLA composites (LCTP) were prepared by laminating PLA film (obtained by hot press method) with CTP also by hot press method at 160 °C. The effect of variation of chitin concentration on the resulting laminated composite's behavior was investigated. The detailed physico-mechanical, surface morphology and thermal were assessed with different characterization technique such as FT-IR, XRD, SEM and TGA. The FTIR spectra showed the characteristic peaks for chitin and PLA in the composites. SEM images showed an excellent dispersion of chitin in the films and composites. Thermogravimetric analysis (TGA) showed that the complete degradation of chitin, PLA film, 5% chitin reinforced PLA film (CTP2) and LCTP are 98%, 95%, 87% and 98% respectively at temperature of 500 °C. The tensile strength of the LCTP was found 25.09 MPa which is significantly higher than pure PLA film (18.55 MPa) and CTP2 film (8.83 MPa). After lamination of pure PLA and CTP2 film, the composite (LCTP) yielded 0.265-1.061% water absorption from 30 min to 24 h immerse in water that is much lower than PLA and CTP. The increased mechanical properties of the laminated films with the increase of chitin content indicated good dispersion of chitin into PLA and strong interfacial actions between the polymer and chitin. The improvement of mechanical properties and the results of antimicrobial and cytotoxicity of the composites also evaluated and revealed the composite would be a suitable candidate for implant application in biomedical sector.
Actionable molecular alterations in advanced gynecologic malignancies: updated results from the ProfiLER program in France
Authors: O. Le Saux, I. Ray-Coquard, V. Corset, E. Sohier, C. Baudet, D. Pissaloux, Q. Wang, S. Chabaud, R. Varnier, P. Heudel, O. Derbel, B. You, O. Trédan, P. Cassier, N. Bonnin, P. Biron, G. Freyer, V. Trillet-Lenoir, T. Bachelot, D. Pérol, J-Y Blay
Journal: Annals of Oncology (2017)
Adjuvant Ipilimumab for Melanoma—The $1.8 Million per Patient Regimen
Authors: Daniel A. Goldstein
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Paludismo de aeropuerto : una enfermedad poco frecuente y casi desconocida
Authors: J Mouchet
Journal: Eurosurveillance (2000)

El articulo de Daniel Lusina y colaboradores que publicamos en esta edicion de Eurosurveillance (1) es un recordatorio oportuno acerca del riesgo que presenta el paludismo de aeropuerto. Desde 1977, ano en que se documento por primera vez esta enfermedad, en Europa occidental se han notificado 75 casos de paludismo de aeropuerto, de los cuales 28 se produjeron en Francia. Los pacientes fueron infectados en Europa sin haber permanecido en zonas endemicas en ningun momento, lo que suscita el problema de una enfermedad poco frecuente que no es sistematicamente investigada en examenes de laboratorio.
Caspase-11–mediated endothelial pyroptosis underlies endotoxemia-induced lung injury
Authors: Kwong Tai Cheng, Shiqin Xiong, Zhiming Ye, Zhigang Hong, Anke Di, Kit Man Tsang, Xiaopei Gao, Shejuan An, Manish Mittal, Stephen M. Vogel, Edward A. Miao, Jalees Rehman, Asrar B. Malik
Journal: Journal of Clinical Investigation (2017)

Acute lung injury is a leading cause of death in bacterial sepsis due to the wholesale destruction of the lung endothelial barrier, which results in protein-rich lung edema, influx of proinflammatory leukocytes, and intractable hypoxemia. Pyroptosis is a form of programmed lytic cell death that is triggered by inflammatory caspases, but little is known about its role in EC death and acute lung injury. Here, we show that systemic exposure to the bacterial endotoxin lipopolysaccharide (LPS) causes severe endothelial pyroptosis that is mediated by the inflammatory caspases, human caspases 4/5 in human ECs, or the murine homolog caspase-11 in mice in vivo. In caspase-11-deficient mice, BM transplantation with WT hematopoietic cells did not abrogate endotoxemia-induced acute lung injury, indicating a central role for nonhematopoietic caspase-11 in endotoxemia. Additionally, conditional deletion of caspase-11 in ECs reduced endotoxemia-induced lung edema, neutrophil accumulation, and death. These results establish the requisite role of endothelial pyroptosis in endotoxemic tissue injury and suggest that endothelial inflammatory caspases are an important therapeutic target for acute lung injury.
A retrospective study of the management of metastatic renal cell carcinoma brain tumors
Authors: G. Klausner, I. Troussier, G. Malouf, L. Feuvret, J. Jacob, J-M. Simon, C.H. Canova, I. Lamproglou, P-Y. Borius, C. Valery, P. Cornu, M. Rouprêt, J-J. Mazeron, J-P. Spano, P. Maingon
Journal: Annals of Oncology (2017)
Fosaprepitant reduces the impact of nausea on daily function during five weeks of chemo-radiotherapy: A sub-study of the GAND-emesis trial
Authors: C.H. Ruhlmann, T.B. Christensen, L. Hammer Dohn, M. Paludan, E. Roennengart, F. Hilpert, P. Feyer, G. Kristensen, O. Hansen, D. Keefe, J. Herrstedt
Journal: Annals of Oncology (2017)
Surto de gastroenterite de origem hídrica em turistas espanhois na República Dominicana em Agosto de 2002
Authors: A Paez Jimenez, R Pimentel, M V Martinez de Aragon, G Hernández Pezzi, S Mateo, J. F. Martinez Navarro
Journal: Eurosurveillance (2004)

No dia 3 de setembro de 2002, o Servicio de Epidemiologia de Asturias informou o Centro Nacional de Epidemiologia (CNE, Espanha) da existencia de um grande numero de casos de gastroenterite em turistas que tinham viajado a um hotel de Punta Cana (Republica Dominicana) em varias datas de agosto. Nas amostras de fezes de alguns casos que tinham consultado um medico nesse pais tinham-se visualisado quistos de Entamoeba hystolityca.
O CNE communicou a possivel existencia de um surto as Autoridades Sanitarias de Republica Dominicana e aos servicios de epidemiologia das sete Comunidades Autonomas espanholas de onde provinham os casos, de modo que se iniciou uma investigacao coordonada. 
A analise descritiva dos 76 casos em turistas espanhois permitiu de estimar a duracao media da doenca a 5.1+ 2.9 dias e o periodo de exposicao a 3.6+ 2.2 dias.
Apos um estudo de coorte, foi estabelecida uma taxa de ataque de 32.4%. Assumindo o mesmo nivel de exposicao para toda a coorte, estima-se que 216 (95% CI=114.75-317.25) turistas espanhois teriam apresentado sintomas.
Nenhuma das amostras de fezes provindo dos casos que apresentavam sintomas ao retorno mais que nao tinham recebido tratamento foram positivas para E. hystolityca. 
No 10 de setembro de 2002, um inquerito ambiental foi realizado no hotel. Amostras de gelo e de varios alimentos servidos nesse dia no buffet apresentavam coliformes. 
O consumo de agua de torneira do hotel foi o unico factor de risco associado com a presenca de sintomas (RR= 3.55; 95% CI =1.13-10.99). 
E indispensavel garantir a qualidade da agua de consumo e o nivel minimo de formacao dos manipuladores de alimentos neste tipo de estabelecimentos para evitar surtos similares no futuro.
Baseline gut microbiota in metastatic melanoma patients treated with ipilimumab: Relation with clinical response and colitis
Authors: N. Chaput, P. Lepage, C. Coutzac, E. Soularue, V. Asvatourian, E. Lanoy, C. Mateus, F. Carbonnel, C. Robert
Journal: Annals of Oncology (2017)
Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)
Authors: R.S. Finn, M. Kudo, A-L. Cheng, L. Wyrwicz, R. Ngan, J-F. Blanc, A.D. Baron, A. Vogel, M. Ikeda, F. Piscaglia, K-H. Han, S. Qin, Y. Minoshima, Y. Funahashi, M. Ren, R. Dairiki, P. Sachdev, T. Tamai, C. Dutcus, T.R.J. Evans
Journal: Annals of Oncology (2017)
GW28-e1209 Whole Exome Sequencing Identified a Pathogenic Mutation in RYR2 in a Chinese Family with Unexplained Sudden Death
Authors: Yubi Lin, Zili Liao, Siqi He, Ruilin Liu, Yongzheng Peng, Nan Yu, Hang Qi, Jia Chen, Ruiling Feng, Zifeng Huang, Heping Lei, Yang Liu, Fang Rao, Chunyu Deng, Yumei Xue, Kejian Wang, Bin Zhang, Hua Yao, Shulin Wu
Journal: Journal of the American College of Cardiology (2017)
Impact of a cancer care coordination program based on health information technologies for patients treated by oral anticancer therapy: The CAPRI randomized trial
Authors: M. Ferrua, M. Di Palma, F. Lemare, A. Fourcade, B. Lalloue, F. Daumas - Yatim, M. Guillet - Lacaze, E. Minvielle
Journal: Annals of Oncology (2017)
Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients
Authors: M. Lambertini, O. Goldrat, A.R. Ferreira, J. Dechene, H.A. Azim Jr, J. Desir, A. Delbaere, M.-D. t’Kint de Roodenbeke, E. de Azambuja, M. Ignatiadis, I. Demeestere
Journal: Annals of Oncology (2017)